|
The document discusses a submission by 3M to the EPA regarding a follow-up study on health conditions, specifically bladder cancer and other health endpoints, among workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, including a report from the University of Minnesota on self-reported medical conditions.
|
2006 |
AR226-3731
|
V36J8MRxrZKkYanvB7zO868YK |
2 |
|
3M submitted additional information to the EPA regarding a health study on perfluorooctanesulfonyl fluoride (POSF) manufacturing workers, which included a report on self-reported medical conditions and confirmed that there was no excess incidence of bladder cancer among the workers, despite previous findings of excess bladder cancer mortality.
|
2006 |
AR226-3731
|
rxmqvE9EwQjqoEOkk0brzXoGV |
2 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study related to perfluorooctanesulfonyl fluoride (POSF) manufacturing workers, highlighting a final report on self-reported medical conditions that examined various health endpoints, including cancer.
|
2006 |
AR226-3731
|
Gmnw9OZN30dVzvyzDzXMrjadv |
2 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
G6yjvQOvEQB0V3woN5O66x6V |
2 |
|
The document discusses a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
KRn2jeq9ZZoLOdMKKoxLJ2mBN |
2 |